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We are most grateful to Dr. Floria et al. for showing such 
an avid interest in our work [1].
As we stated in the abstract and the introduction of the 
manuscript, the Systemic COronary Risk Estimation (SCORE) 
model is recommended for the assessment of cardiovascular 
disease (CVD) death risk in individuals free of CVD, therefore 
we agree with your comment on it. The link between the 
SCORE result (assessment of total cardiovascular risk factor 
estimation) and carotid-femoral pulse wave velocity (CFPWV) 
is not well documented and indirectly estimates how the latter 
affects the 10-year risk of death (fatal atherosclerotic event) 
due to CVDs. Moreover, the aim of our study was to determine 
the association between CFPWV and SCORE result, and to 
describe the distribution of CFPWV in the adult, urban Polish 
population. As mentioned in the manuscript [1], our study 
participants were citizens of Krakow, Poland (n = 1008) who 
were free of CVD at the time of enrolment. Afterwards, they 
were visited at home to complete a structured questionnaire 
and then invited to a clinic for a physical examination and 
a profound medical interview to evaluate the comorbidities 
and medications. As suspected, some of them were diagnosed 
with CVD after the initial analysis. As stated in the current 
European Society of Cardiology (ESC) guidelines, total cardio-
vascular risk estimation (SCORE) is recommended for people 
over 40 years of age, unless they are categorised as high- or 
very-high–risk based on documented CVD, type 2 diabetes, 
kidney disease, or a highly elevated single risk factor [2]. In our 
study, the analysis of SCORE was performed after exclusion of 
patients with established coronary artery disease or type 2 dia-
betes. As you have correctly noticed, approximately 60% of 
subjects with moderate SCORE results have CVD [3]. We agree 
that more frequent follow-up in these patients is important in 
the context of avoiding a possibly fatal cardiovascular event.
We are familiar with the 2016 European guidelines on 
CVD prevention in clinical practice, which currently do not 
recommend the use of pulse wave velocity (PWV) in routine 
clinical practice [2]. However, in the same guidelines the 
authors state that aortic stiffness expressed as PWV is a strong 
predictor of future cardiovascular events and all-cause mor-
tality [2, 4]. Moreover, our study was started before the new 
2016 ESC guidelines were published; therefore, the inclusion 
criteria and recommendations were based on the previous 
ESC guidelines. Hence, in our opinion, it seems that in some 
cases it is worth using CFPWV, at least in the higher-risk 
population, to assess future cardiovascular events. Moreover, 
as you correctly noticed, we found a significant positive as-
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sociation between high cardiovascular risk (SCORE > 5%) 
and high CFPWV. Nevertheless, we agree that identifying 
new instruments for detecting subclinical organ damage and 
cardiovascular risk is still desirable. 
Finally, as you mentioned, by calculating a cut-off value 
of CFPWV we wanted to differentiate the high-risk Polish 
population (SCORE ≥ 5%). In our study SCORE ≥ 5% indepen-
dently predicted high CFPWV (in 4.9 years of follow-up), and 
CFPWV > 11.7 m/s was most valid in relation with high CVD 
risk. Our result is in line with the 2016 ESC guidelines demon-
strating a conservative estimate of significant alterations of aor-
tic function in middle-aged hypertensive patients — 12 m/s [2]; 
however, hypertension-mediated organ damage can be sus-
pected in patients with CFPWV exceeding 10 m/s [5].
In conclusion, we agree that SCORE risk assessment 
should be performed in apparently healthy populations. How-
ever, despite an in-depth initial clinical evaluation, recognising 
the condition of “the apparent health” is a challenge. Future 
studies should focus on the subclinical manifestations of CVD, 
particularly in asymptomatic individuals.
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